logo

For the Inventor, By the Inventor

Hillsborough, NJ, United States of America

Hong Liu

This inventor holds 30 USPTO granted patents and 14 published patent applications and 20 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Merck Sharp & Dohme LLC. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Liu. Retrieved from https://idiyas.com/inventor/hong-liu-98mdhkkq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 30 

% Patents Active = 93.3

 

Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 74(Granted Patents)


Location History:

  • River Edge, NJ (US) (2006 - 2008)
  • Hackensack, NJ (US) (2005 - 2010)
  • Kenilworth, NJ (US) (2013 - 2020)
  • Hillsborough, NJ (US) (2012 - 2023)

Company Filing History:

goldMedal22 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal6 out of 1,829 
 
Schering Corporation
 patents
bronzeMedal2 out of 72 
 
Merck Sharp & Dohme LLC
 patents
4. 2 out of 7 
 
Msd Italia S.r.l.
 patents
where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
NaV1.8 Inhibitors
Bile Acid Modulation
Viral Disease Treatments
Leucine-Rich Repeat Kinase
Adenosine A2a Receptor Antagonists
Cycloalkyl Compounds
Oxazolidine Compounds
Tetracyclic Heterocycles
BACE Inhibitors
Substituted Benzofuran
Iminothiadiazepane
Heterocyclic Derivatives
30 patents (USPTO):Explore Patents
1. 12723035 - Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as Nav1.8 inhibitors (2026-09-01),
2. 12516046 - 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors (2026-01-06),
3. 12246008 - 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels (2025-03-11),
4. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors (2025-01-14),
5. 11802122 - 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors (2023-10-31),
6. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors (2022-07-05),
7. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),
8. 10414775 - Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease (2019-09-17),
9. 10414774 - Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease (2019-09-17),
10. 10047098 - C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use (2018-08-14),
11. 9809568 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-11-07),
12. 9745324 - Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use (2017-08-29),
13. 9718818 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-08-01),
14. 9688654 - Compounds inhibiting leucine-rich repeat kinase enzyme activity (2017-06-27),
15. 9573939 - Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases (2017-02-21),

Title: The Innovative Work of Hong Liu in Advancing Pain Management Therapies

Introduction

Hong Liu, based in Hillsborough, NJ, is an accomplished inventor with a significant portfolio of 27 patents. His innovative contributions primarily focus on the development of novel pharmaceutical compounds aimed at treating various pain-related disorders.

Latest Patents

Among his latest inventions are two notable patents: the first relates to "2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors." These compounds are designed to inhibit Na1.8 channel activity and hold potential for treating and managing pain disorders, cough disorders, as well as acute and chronic itch disorders. The second patent concerns "2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors," which serves a similar therapeutic purpose. Both patent families are groundbreaking in their approach to channel activity modulation, providing promising avenues for medical advancements.

Career Highlights

Hong Liu has significantly impacted the pharmaceutical field through his work with renowned companies such as Merck Sharp & Dohme Corporation and Schering Corporation. His tenure at these leading institutions allowed him to refine his research and development skills, contributing to numerous innovative medicines that address critical health issues.

Collaborations

Throughout his career, Hong has collaborated with talented professionals including Xing Dai and Bernard R. Neustadt. These partnerships have enabled the synthesis of innovative ideas and research methodologies, further enhancing the quality and applicability of his inventions.

Conclusion

Hong Liu stands out as a notable inventor whose work has the potential to significantly influence the treatment landscape for pain and itch disorders. With a track record of successful patents and collaborations, he continues to push the boundaries of pharmaceutical research, making considerable contributions to the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…